Record Increase in Adult ADHD Diagnoses
A new study from Canada indicates a historic rise in stimulant prescriptions among adults, doubling since the onset of the COVID-19 pandemic. This trend parallels similar increases observed in countries like the U.S., Australia, the U.K., and Finland.
Healthcare professionals believe these findings confirm the trends they have been witnessing in clinical practices.
Demographic Shifts Revealed
The research, which analyzed data from January 2016 to June 2024, highlights significant changes in the demographics of individuals receiving stimulant prescriptions. Before the pandemic, 48% of new recipients were female; this figure surged to 59% during the pandemic, with the most notable increase observed in adults aged 25 to 34.
Increased Prescription Rates
By June 2024, the monthly prescription rate for adults reached 10.4 per 1,000 people, representing over a sevenfold increase since the study’s commencement. While this uptick may suggest improved care, it raises concerns about the thoroughness of patient evaluations.
Expert Opinions on the Spike
Dr. Nissa Keyashian, a California psychiatrist, commented on the trend, noting, "In my practice, many have received a new diagnosis of ADHD, often the inattentive subtype, in adulthood." She explained that many women with unrecognized symptoms often struggle with organization and focus.
Jonathan Alpert, a New York City psychotherapist, added that many adults face challenges in a demanding digital environment that can resemble ADHD symptoms but are not necessarily indicative of the disorder. He cautioned against conflating everyday difficulties with clinical diagnoses.
Prescriptions and Telehealth Dynamics
The study also uncovered a shift in who prescribes these medications. Although prescriptions from psychiatrists have remained steady, there has been a significant increase from primary care physicians and nurse practitioners. Keyashian suggested that the rise of telehealth during the pandemic may have led to increased diagnoses, with some individuals potentially misdiagnosed.
"Medication should not become a performance enhancer," Alpert highlighted, warning that this could lead to psychological reliance.
Study Limitations and Recommendations
Researchers acknowledged some limitations, such as a lack of detailed medical records and the uncertainty regarding the applicability of findings across various regions. They noted that some stimulants may have been prescribed off-label for anxiety, which also surged during the pandemic.
For those suspecting they may have ADHD, Keyashian recommends consulting with a psychiatrist experienced in ADHD diagnostics. "It's advisable to discuss your physician's expertise in this area," she urged.
As Alpert remarked, "Many people today feel mentally scattered. The challenge is determining whether we're seeing an increase in ADHD or simply the cognitive strain from living in a hyper-distracted world."
This significant research was published in the Canadian Medical Association Journal.